Evidence map›Paper›PMID 34597526›Full record

ArticleHuman vaccines & immunotherapeutics2021

How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules.

A Campanati, E Martina, F Diotallevi, G Radi, G Kontochristopoulos, D Rigopoulos, S Gregoriou, A Offidani

Open access · hybridAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

A CampanatiDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.ORCID 0000-0002-3740-0839
E MartinaDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
F DiotalleviDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
G RadiDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
G Kontochristopoulos1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
D Rigopoulos1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
S Gregoriou1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
A OffidaniDermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
Marche Polytechnic University · ITNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All public health ministries have implemented strategies to contain the spread of COVID-19 worldwide. Vaccines against SARS-CoV-2 still represent the most effective weapon to combat the circulation of the virus, in order to decrease the impact of COVID-19 on the general health of the population, to prevent the emergence of new SARS-CoV-2 variants and avoid excessive hospitalization. However, the success of a vaccination campaign largely depends on the penetrance of the message addressed to general population, which takes on an even more strategic value when vaccine candidates suffer from chronic diseases. In this view, patients suffering from immune-mediated skin diseases could represent a "weak link in the vaccine chain." Our main objective is to focus attention on four main elements in support of vaccination strategy in order to promote the patients' awareness to be at highest risk of negative consequences in case of SARS-Cov-2 infection, and to build, strengthen and maintain trust in vaccines' efficacy and safety.

Indexed as

COVID-19Skin DiseasesCOVID-19 VaccinesHumansSARS-CoV-2VaccinationVaccination HesitancyCOVID-19 VaccinesCOVID-19dermatologyhesitancyimmune-mediated skin diseasesvaccines

Identifiers

PMID34597526
PMCPMC8828062
OpenAlexW3202448848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.